Abbott Laboratories
May 7, 2008
Biotech Stocks' Various Lupus Therapies: Opportunity or Lost Cause?
For a long time, few drugs were developed for rheumatological diseases. It was considered unattractive from a commercial viewpoint since relatively few patients suffered from them. via The Biotech Stock Blog
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Abbott profit beats Wall Street estimates for 2Q | Jul 18 | Qamile Stema | 13 |
| FDA panel opposes Depakote warning | Jul 11 | Deeptoad | 1 |
| Sugar in popular Similac Organic baby formula r... | Jun '08 | Wendy | 5 |
| Mylan, Abbott settle anti-seizure drug dispute | Jun '08 | Jim | 1 |
| Abbott drugs in FDA risk reviews | Jun '08 | Corby | 2 |
| Arthritis drugs investigated for link to cancer | Jun '08 | RAG | 4 |
| Vacancies edging up for area's retailers -- Ban... | Jun '08 | speculator | 1 |
Most Popular
